A case of HER2-positive male breast cancer with lung metastases showing a good response to trastuzumab and paclitaxel treatment

Breast Cancer

Volumn 16, Issue 2, 2009, Pages 136-140

  Hayashi, Hironori ^a   Kimura, Mariko ^a   Yoshimoto, Nobuyasu ^a   Tsuzuki, Masanori ^a   Tsunoda, Nobuyuki ^a   Fujita, Takashi ^a   Yamashita, Toshinari ^a   Iwata, Hiroji ^a  

^a AICHI CANCER CENTER HOSPITAL   (Japan)

Author keywords

Asymmetric cell division; HER2; Heterogeneity; Male breast cancer; Trastuzumab

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; PACLITAXEL; PROGESTERONE RECEPTOR; TRASTUZUMAB;

ADVANCED CANCER; AGED; ANEMIA; ARTICLE; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER STAGING; CASE REPORT; COMPUTER ASSISTED TOMOGRAPHY; DISEASE DURATION; DRUG WITHDRAWAL; FOLLOW UP; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LEUKOPENIA; LUNG METASTASIS; MALE; NEEDLE BIOPSY; NEUROPATHY; NEUTROPENIA; PRIORITY JOURNAL; SIDE EFFECT; THORAX RADIOGRAPHY; TREATMENT DURATION;

AGED; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS, MALE; CARCINOMA, DUCTAL, BREAST; HUMANS; IMMUNOENZYME TECHNIQUES; LUNG NEOPLASMS; MALE; PACLITAXEL; PROGNOSIS; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; TOMOGRAPHY, X-RAY COMPUTED; TREATMENT OUTCOME;

EID: 65249176179     PISSN: 13406868     EISSN: None     Source Type: Journal    
DOI: 10.1007/s12282-008-0060-1     Document Type: Article

References (22)

1. SH Giordano AU Buzdar GN Hortobagyi 2002 Breast cancer in men Ann Intern Med 137 8 678 87
2. ZP Pavelic L Pavelic EE Lower M Gapany S Gapany EA Barker HD Preisler 1992 c-myc, c-erbB-2, and Ki-67 expression in normal breast tissue and in invasive and noninvasive breast carcinoma Cancer Res 52 9 2597 602
3. SA McLachlan C Erlichman FF Liu N Miller M Pintilie 1996 Male breast cancer: an 11 year review of 66 patients Breast Cancer Res Treat 40 3 225 30
4. KJ Bloom H Govil P Gattuso V Reddy D Francescatti 2001 Status of HER-2 in male and female breast carcinoma Am J Surg 182 4 389 92
5. A Pich E Margaria L Chiusa 2000 Oncogenes and male breast carcinoma: c-erbB-2 and p53 coexpression predicts a poor survival J Clin Oncol 18 16 2948 56
6. C Rudlowski N Friedrichs A Faridi L Füzesi R Moll G Bastert W Rath R Büttner 2004 Her-2/neu gene amplification and protein expression in primary male breast cancer Breast Cancer Res Treat 84 3 215 23
7. G Gasparini M Gion L Mariani P Papaldo D Crivellari G Filippelli A Morabito V Silingardi F Torino A Spada M Zancan L De Sio A Caputo F Cognetti A Lambiase D Amadori 2007 Randomized Phase II Trial of weekly paclitaxel alone versus trastuzumab plus weekly paclitaxel as first-line therapy of patients with Her-2 positive advanced breast cancer Breast Cancer Res Treat 101 3 355 65
8. HJ Burstein A Keshaviah AD Baron RD Hart R Lambert-Falls PK Marcom R Gelman EP Winer 2007 Trastuzumab plus vinorelbine or taxane chemotherapy for HER2-overexpressing metastatic breast cancer: the trastuzumab and vinorelbine or taxane study Cancer 110 5 965 72
9. V Diéras P Beuzeboc V Laurence JY Pierga P Pouillart 2001 Interaction between Herceptin and taxanes Oncology 2 43 9
10. H Yamauchi V Stearns DF Hayes 2001 The Role of c-erbB-2 as a predictive factor in breast cancer Breast Cancer 8 3 171 83
11. JS Ross JA Fletcher 1998 The HER-2/neu oncogene in breast cancer: prognostic factor, predictive factor, and target for therapy Stem Cells 16 6 413 28
12. G Fountzilas D Tsavdaridis A Kalogera-Fountzila CH Christodoulou E Timotheadou CH Kalofonos P Kosmidis A Adamou P Papakostas H Gogas G Stathopoulos E Razis D Bafaloukos D Skarlos 2001 Weekly paclitaxel as first-line chemotherapy and trastuzumab in patients with advanced breast cancer. A Hellenic Cooperative Oncology Group phase II study Ann Oncol 12 11 1545 51
13. J Wang-Rodriguez K Cross S Gallagher M Djahanban JM Armstrong N Wiedner DH Shapiro 2002 Male breast carcinoma: correlation of ER, PR, Ki-67, Her2-Neu, and p53 with treatment and survival, a study of 65 cases Mod Pathol 15 8 853 61
14. S Huang Y Chen K Podsypanina Y Li 2008 Comparison of expression profiles of metastatic versus primary mammary tumors in MMTV-Wnt-1 and MMTV-Neu transgenic mice Neoplasia 10 2 118 24
15. M Shipitsin LL Campbell P Argani S Weremowicz N Bloushtain-Qimron J Yao T Nikolskaya T Serebryiskaya R Beroukhim M Hu MK Halushka S Sukumar LM Parker KS Anderson LN Harris JE Garber AL Richardson SJ Schnitt Y Nikolsky RS Gelman K Polyak 2007 Molecular definition of breast tumor heterogeneity Cancer Cell 11 3 259 73
16. C Tapia S Savic U Wagner R Schönegg H Novotny B Grilli M Herzog AD Barascud I Zlobec G Cathomas L Terracciano G Feichter L Bubendorf 2007 HER2 gene status in primary breast cancers and matched distant metastases Breast Cancer Res 9 3 R31
17. M Marty F Cognetti D Maraninchi R Snyder L Mauriac M Tubiana-Hulin S Chan D Grimes A Antón A Lluch J Kennedy K O'Byrne P Conte M Green C Ward K Mayne JM Extra 2005 Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group J Clin Oncol 23 19 4247 50
18. DJ Slamon B Leyland-Jones S Shak H Fuchs V Paton A Bajamonde T Fleming W Eiermann J Wolter M Pegram J Baselga L Norton 2001 Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2 N Engl J Med 344 11 783 92
19. AD Seidman MN Fornier FJ Esteva L Tan S Kaptain A Bach KS Panageas C Arroyo V Valero V Currie T Gilewski M Theodoulou ME Moynahan M Moasser N Sklarin M Dickler G D'Andrea M Cristofanilli E Rivera GN Hortobagyi L Norton CA Hudis 2001 Weekly trastuzumab and paclitaxel therapy for metastatic breast cancer with analysis of efficacy by HER2 immunophenotype and gene amplification J Clin Oncol 19 10 2587 95
20. M Varna H Soliman JP Feugeas E Turpin D Chapelin L Legrès LF Plassa A de Roquancourt M Espié JL Misset A Janin H de Thé P Bertheau 2007 Changes in allelic imbalances in locally advanced breast cancers after chemotherapy Br J Cancer 97 8 1157 64
21. B Czerniak F Herz RP Wersto LG Koss 1992 Asymmetric distribution of oncogene products at mitosis Proc Natl Acad Sci USA 89 11 4860 3
22. WF Anderson R Matsuno 2006 Breast cancer heterogeneity: a mixture of at least two main types? J Natl Cancer Inst 98 14 948 51